Status:
COMPLETED
TS Gene Polymorphism Predicts Effect in Patients With Advanced Lung Cancer
Lead Sponsor:
Hunan Province Tumor Hospital
Conditions:
Non-small-cell Lung Cancer
Adenocarcinoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The investigators performed a multicenter, open trial of using TS gene polymorphism to predict advanced lung adenocarcinoma effect to pemetrexed combined with cisplatin regiment as first-line treatmen...
Detailed Description
1. Main eligibility criteria were histologic or cytologic proof of advanced non-small-cell lung cancer (NSCLC) primary treatment, normal organ function, and Eastern Cooperative Oncology Group performa...
Eligibility Criteria
Inclusion
- histologic or cytologic proof of advanced lung adenocarcinoma
- primary treatment
- normal organ function
- Eastern Cooperative Oncology Group performance status 0 to 2
Exclusion
- Symptomatic patients with brain metastases
- Major organ dysfunction and severe heart disease
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2015
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00940069
Start Date
March 1 2009
End Date
January 1 2015
Last Update
February 22 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
HuNan province tumor hospital
Changsha, Hunan, China, 410013